Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm ...

2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...

Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

A native of De Pere, Wisconsin, Kinziger is considered a four-star recruit by 247Sports, On3 and ESPN. 247Sports ranks the ...

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

Citi has started coverage of Gilead Sciences (NASDAQ:GILD) and Vertex Pharmaceuticals (NASDAQ:VRTX) at buy saying the former will benefit from short-term growth of Biktarvy (bictegravir, emtricitabine ...

In a report released today, Umer Raffat from Evercore ISI maintained a Buy rating on Amgen (AMGN – Research Report). The company’s ...

The Dow Jones Industrial Average fell 382.15 points, or 0.86%, to 43,910.98, the S&P 500 lost 17.36 points, or 0.29%, to ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...